T he identification of predictive biomarkers for disease risk is fundamental to precision medicine. 1, 2 High-throughput nuclear magnetic resonance metabolomics profiling of prospective cohorts has recently revealed that elevated blood concentrations of glycoprotein acetyls (GlycA) are a strong predictive biomarker for long-term risk of morbidity and mortality from diverse diseases, many of which are associated with chronic inflammation. 3, 4 GlycA levels have been found to predict risk from cardiovascular diseases, [5] [6] [7] [8] certain cancers, 6 ,7,9 type 2 diabetes mellitus, 10, 11 nonalcoholic fatty liver, 12 chronic inflammatory conditions, 7 severe infections, 13 and all-cause mortality. 6, 7 GlycA itself is a heterogeneous nuclear magnetic resonance signal quantifying the combined levels of at least 5 circulating glycoproteins that are mainly produced in liver [13] [14] [15] and has long been known to elevate with acute inflammation and can remain elevated fortnight after infectious disease. [14] [15] [16] [17] [18] [19] Recently, in asymptomatic individuals and GlycA has recently been found to denote subclinical chronic inflammation in asymptomatic individuals, as well. 13 Chronic inflammation is an important factor in the pathogenesis and severity of numerous age-related conditions and diseases. 20, 21 For example, GlycA-associated chronic inflammation has been shown to modify the risk prediction capability of HDL (high-density lipoprotein) in secondary prevention of cardiovascular disease. 22 Importantly, in many studies, GlycA's predictive effect has been shown to be independent of hsCRP (high-sensitivity C-reactive protein)-the current standard biomarker for inflammation. For instance, Muhlenstein et al 23 showed that GlycA is potentially an independent predictor of secondary major cardiac events in angiography patients. Although GlycA is predicting risk of incident disease or poor prognosis, independent of hsCRP, a systematic evaluation of the spectrum of cause-specific death and hospitalization associations for GlycA has been lacking.
Here, we evaluate GlycA as a biomarker for future risk of hospitalization or death across the spectrum of all common diseases of 2 independent populationbased cohorts with complete 8-year electronic health record (EHR) follow-up. We further demonstrate and corroborate the potential of chronic inflammation for stratifying long-term risk of cardiovascular mortality in a cohort of patients with suspected heart attack. Our findings identify several diseases for which GlycA could enable better risk assessment in primary prevention and suggest potential for GlycA in secondary prevention of angiography patients.
METHODS
The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedure. Data on biomarker concentrations and disease outcomes from FINRISK are available through application to the biobank of Finnish National Institute for Health and Welfare and from the ANGES (Angiography and Genes Study) cohort through the study investigators after necessary applications and transfer agreements are in place. All studies have been approved by institutional ethics committees, and the participants have given their informed consent. Detailed description of the study cohorts, data processing, EHRs, and statistical analyses is provided in the Data Supplement.
RESULTS
To elucidate the cause specificity of the disease burden predicted by elevated GlycA, we utilized high-throughput nuclear magnetic resonance spectroscopy data with matched EHRs obtained from national care register for health care and causes of death registries from the independent population-based FINRISK 1997 (n=7321) and Dietary, Lifestyle, and Genetic Determinants of Obesity and Metabolic Syndrome (DILGOM) (n=4540) cohorts [24] [25] [26] Only the first incident of each outcome (either a hospital discharge diagnosis or mortality) was considered for each individual. Main and side causes of diagnosis were treated equally when collating outcomes. For each outcome analyzed, participants with prevalent events of the same outcome were excluded. We tested GlycA for association with all 468 disease outcomes that had >10 incident cases in both DILGOM and FINRISK 1997 (full listing in Table III in the Data Supplement) during an 8-year follow-up period (the maximum follow-up time available for DILGOM). Cox proportional hazards models were fit for each outcome separately with age as time scale and adjusting for smoking, body mass index, sex, systolic blood pressure, alcohol consumption, as well as 3 all-cause mortality biomarkers previously identified alongside GlycA in FINRISK 1997: citrate, VLDL (very-low-density lipoprotein) particle size, and albumin. 6 Individuals with any previous incidents of the same outcome within the 10 years before sample collection for FINRISK 1997 and 20 years before sample collection for DILGOM (hereby prevalent cases) were excluded when analyzing each outcome. We considered GlycA to be the biomarker for any outcome that was nominally significant (P<0.05) in both FINRISK 1997 and DILGOM and statistically significant after correcting for multiple testing (P<1.1×10 −4 ; adjusting for the 468 tested outcomes) in an inverse-variance weighted meta-analysis of FINRISK 1997 and DILGOM ( Figure 1 ).
In total, we observed strong and consistent associations between elevated GlycA concentrations and increased risk for 16 Table IV in the Data Supplement). Consistent with previous biomarker studies of GlycA, we observed significant and replicable associations ; adjusting for the 468 tested outcomes) and nominally significant (P<0.05) in both cohorts. HRs and 95% CIs are shown on a natural logarithm scale. Individual cohort results are presented in Figure I in the Data Supplement, and HRs are detailed in Table IV in the Data Supplement. The spectrum of disease risk was analyzed for 468 diagnosis outcomes with >10 events in both cohorts during an 8-y follow-up. Alphanumeric codes in the square brackets indicate the ICD-10 codes/categories for each outcome. Cox models were fit using age as the time scale adjusting for sex, smoking status, body mass index, blood pressure, alcohol consumption, and previously discovered biomarkers for 5-y all-cause mortality (citrate, albumin, and VLDL [very-low-density lipoprotein] particle size) to elucidate biology behind GlycA specific mortality risk. All available prevalent cases within before GlycA measurement were excluded for each association test (Methods). DILGOM indicates Dietary, Lifestyle, and Genetic Determinants of Obesity and Metabolic Syndrome.
with cardiovascular diseases, type 2 diabetes mellitus, and respiratory infections (Figure 1) ), neither of which have yet been investigated by any GlycA biomarker study. Elevated GlycA was also associated with increased 8-year risk of chronic obstructive pulmonary disease (HR, 1.58; 95% CI, 1.27-1.96; P=3×10 −5 ). Previous studies of GlycA as a biomarker for cardiovascular disease have used broad definitions encompassing a variety of diseases of the cardiovascular system. [5] [6] [7] From our analyses, we were able to identify the specific cardiovascular diseases predicted by GlycA. ), and chronic ischemic heart disease (HR, 1.27; 95% CI, 1.13-1.44; P=9×10 HRs for GlycA were not attenuated when adjusting models for prevalent cases of each outcome as a covariate rather than excluding them ( Figure II in the Data Supplement). Adjustment rather than exclusion of prevalent cases led to an increase in power for several outcomes, resulting in additional significant associations ( Figure III in the Data Supplement; Table V in the Data Supplement). We recovered previously observed associations between elevated GlycA and intestinal infections, 13 as well as hypertension, 8 and observed novel associations with 8-year risk of inflammatory polyarthropathies (HR, 1.46; 95% CI, 1.28-1.68; P=4×10 −8 ), and glomerular diseases (HR, 1.95; 95% CI, 1.49-2.56; P=1×10 −6 ). HRs were only weakly attenuated when adjusting for hsCRP ( Figure IV in the Data Supplement), consistent with previous observations that GlycA is largely independent of hsCRP and may be reflective of a more diverse component of the inflammatory response. The statistical models were stable when comparing the minimally adjusted models (age and sex only) to fully adjusted model ( Figure V in the Data Supplement).
To corroborate the validity of EHR-wide analyses, we compared the disease association results to adjudicated end points for major common diseases (cardiovascular disease subtypes, type 2 diabetes mellitus, chronic obstructive pulmonary disease, kidney failure, and any cancer) collated based on health information across national health registries, as well as reimbursement information. Our results show consistent associations of EHR mining with those from predefined and widely used adjudicated end points (Methods; Figure VI in the Data Supplement; Table VI in the Data Supplement).
We further performed sensitivity analysis where we compared the HRs of using age as time scale to using age as a covariate and follow-up time as time scale. We found that the main results were comparable with both approaches (Methods; Figure VII in the Data Supplement).
Finally, we investigated the potential utility of GlycA as a biomarker in secondary prevention in 900 angiography patients from the ANGES study 27 during a 12-year followup period (Methods). Baseline cohort characteristics are described in the Table. Their baseline mortality risk during the 12-year follow-up was 27% for all-cause mortality and 14% for cardiovascular mortality. We found GlycA was strongly associated with both 12-year all-cause mortality (HR, 1.43; 95% CI, 1.21-1.70; P=4×10 follow-up as the time scale and adjusting for significant covariates (Methods). When partitioning the angiography patients by GlycA quintiles, we observed a prominent increase in cardiovascular mortality risk when the quintiles were added to the multivariable model ( Figure 2 ; ; n=900 with 128 deaths; Methods). Use of ACE (angiotensin-converting-enzyme) inhibitor showed strong association with reduced risk in the multivariable model (HR, 0.41; 95% CI, 0.28-0.60; P=6×10 −6 ). We further compared the predictive ability of GlycA and hsCRP for cardiovascular mortality among patients undergoing angiography. GlycA and hsCRP were both significantly associated with cardiovascular mortality when analyzed separately in covariate-adjusted models (HR, 1.69; 95% CI, 1.32-2.16; P=3×10 −5 and HR, 1.61; 95% CI, 1.33-1.96; P=1×10 −6 , respectively). When the 2 inflammatory markers were included simultaneously in the multivariable model, the HRs for both GlycA and hsCRP were attenuated but remained strongly predictive (HR, 1.37; 95% CI, 1.04-1.81; P=2×10 −2 and HR, 1.45; 95% CI, 1.17-1.80; P=8×10 −4 , respectively). When partitioning the angiography patients by hsCRP quintiles, we observed an increase in cardiovascular mortality risk across increasing hsCRP concentrations (Table VIII in the Data Supplement). Angiography patients in the fourth and fifth hsCRP quintiles were at 3.12 and 4.61× increased risk of cardiovascular mortality when compared with those in the lowest quintile.
DISCUSSION
GlycA is a heterogeneous biomarker associated with both acute and chronic inflammation that has been of intense, recent interest as a biomarker for diverse disease outcomes both in asymptomatic people and in those with preexisting chronic disease. 3 In this study, we performed the first systematic evaluation of GlycA as a reproducible biomarker for onset of all common disease outcomes, using data from 11 861 adults from 2 independent population-based cohorts with complete EHR during an 8-year follow-up period. In addition to recapitulating previously observed GlycA associations, [5] [6] [7] [8] 10, 11, 13 we observed novel associations between elevated GlycA and 8-year risk of alcoholic liver disease, chronic renal failure, glomerular diseases, chronic obstructive pulmonary disease, and inflammatory polyarthropathies and identified the specific cardiovascular diseases underlying the established GlycA-associated risk of overall cardiovascular disease risk. Our results show that chronic inflammation increases risk of diseases systematically across large internal organs. Specifically, our novel results show that GlycA presents an extremely strong association with liver and kidney disease risk. We further showed potential utility of GlycA for stratifying a 5-fold risk of cardiovascular mortality among 900 angiography patients already at elevated risk for recurrent, severe cardiovascular disease events.
We examined the landscape of disease associations for GlycA based on complete EHRs from hospital discharge and death registries. However, as a limitation, we did not include records from primary-care health centers in the analyses because the data were incompletely available, and the validation of the diagnoses may vary considerably. In contrast, the validity of the nation-wide Finnish Hospital Discharge Register Diagnoses has been examined in numerous studies and found to be robust. 28 Consistent with this, we performed sensitivity analyses using predefined end points of major diseases defined by adjudicated compilation of hospital and reimbursement registries, and the HRs were in agreement with our results using the EHR mining of hospital and death registries. Another limitation is the set of fixed covariates we selected for the EHR analyses because of the exploratory nature of the study. It may well be that for some outcomes, there may be other clinical covariates that might attenuate the GlycA HRs. Therefore, further studies should evaluate an optimal covariate model for the individual outcomes to obtain more precise estimate.
We aimed to evaluate whether GlycA would provide additional information over and above hsCRP for prediction of disease onset and prognosis. GlycA associations across a majority of end points remained essentially unchanged when adjusted for hsCRP, thus demonstrating added predictive value of GlycA. Because hsCRP is well-known predictor of morbidity and mortality in secondary prevention of cardiovascular disease, 29 we assessed whether GlycA could provide independent information on top of hsCRP to discriminate prognosis among patients undergoing angiography. The difference in absolute cardiovascular mortality risk was 16% between top and bottom quintiles of GlycA, raising the prospect for personalized treatment strategies. Although GlycA was comparable with hsCRP in risk stratification in angiography patients, both biomarkers remained predictive in the multivariable model. Our findings are in line with Muhlenstein et al, 23 where they showed that GlycA and hsCRP are potentially independent predictors of death, major cardiac events, and heart failure hospitalization when categorizing the patients for high/low GlycA and hsCRP. However, further studies are required to corroborate and validate whether GlycA could be used in secondary prevention in concert with hsCRP to assess mortality risk for angiography patients.
The question remains as to how to reduce risk for individuals with elevated GlycA. The association between GlycA, increased inflammation, and disease severity in patients with chronic disease [16] [17] [18] in conjunction with the involvement of chronic inflammation in disease pathogenesis 20, 21 suggests the underpinnings of the associated disease risk likely lie in the low-grade chronic inflammation observed in asymptomatic adults with high GlycA levels. 13 It could be considered that GlycA is a marker of general frailty through increased inflammatory burden, and additional disease challenge posed on top of the inflammatory burden leads to poor prognosis. The recent success of the anti-inflammatory drug canakinumab in reducing cardiovascular disease events with the unexpected benefit of reduced rates of lung cancer 30, 31 suggests anti-inflammatory treatment may be beneficial for reducing rates of other diseases predicted by elevated GlycA. Supporting this, antitumor necrosis factor therapy (an anti-inflammatory) was found to reduce GlycA levels, disease severity, and vascular inflammation in 16 patients with psoriasis. 18 However, challenges remain in the development of anti-inflammatories for treating chronic disease because inflammation plays a critical role in immune response and tissue repair. 32 In the Canakinumab trial, increased rates of fatal infections and sepsis were observed in the treatment group. 31 Further work is required to determine strategies to mitigate the increased risk of severe infections when using canakinumab. Our sensitivity analyses suggest that the use of ACE inhibitors may reduce the risk indicated by high chronic inflammation; however, our finding should be validated by further studies.
In recent years, EHRs have emerged as a powerful tool for identification of robust biomarkers from high-throughput omics platforms in population-based cohorts. However, the underlying biology and the biomarker involvement in different diseases are often missed. This study demonstrates the validity of such an approach through the GlycA biomarker and may serve as a framework for future systems-level analyses of biomolecular data with linked EHRs in large-scale cohorts, such as national biobanks for a better understanding of a novel biomarker.
